Related Experiment Video
Updated: Feb 7, 2026
08:53
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
10.5K
Hodgkin lymphoma in elderly patients
Sven Borchmann1,2,3, Andreas Engert1, Boris Böll1
1Department I of Internal Medicine, German Hodgkin Study Group (GHSG).
Current Opinion in Oncology
|July 12, 2018
Summary
Curative treatment is feasible for elderly Hodgkin lymphoma patients across all stages. Novel therapies like brentuximab vedotin show promise, but long-term efficacy for relapsed/refractory cases requires further study.
Area of Science:
- Hematology
- Oncology
- Geriatric Medicine
Background:
- Hodgkin lymphoma (HL) predominantly affects younger individuals, but incidence increases in older adults.
- Treatment strategies for elderly HL patients require careful consideration of comorbidities and age-related physiological changes.
Purpose of the Study:
- To review current knowledge on treating elderly Hodgkin lymphoma patients.
- To focus on evidence from clinical trials and the role of novel therapeutic agents.
Main Methods:
- Systematic review of clinical trial data and published literature.
- Analysis of treatment outcomes for elderly patients with newly diagnosed, relapsed, or refractory HL.
- Evaluation of novel drugs, including antibody-drug conjugates and immune checkpoint inhibitors.
Main Results:
- Curative-intent treatment is recommended for elderly HL patients without significant comorbidities, with tailored chemotherapy and radiotherapy regimens based on stage.
- Brentuximab vedotin demonstrates high response rates in elderly patients but has limited durability.
- Anti-PD-1 antibodies offer a distinct mechanism of action and potential efficacy in this population.
Conclusions:
- Curative treatment approaches are achievable for newly diagnosed elderly HL patients in all stages.
- Palliative care is often the primary goal for relapsed/refractory elderly HL patients.
- Further research is needed to determine if novel agents can improve outcomes for relapsed/refractory elderly HL.
Related Concept Videos
01:13Patient-centered Care
3.1K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
01:15Drug Dosing: Geriatric Patients
278
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
01:21Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
239
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
239
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
266
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
317
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
317